We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Reveals Extent of Brain Damage

By LabMedica International staff writers
Posted on 27 Mar 2013
An immunoassay has been used to assess the extent of brain damage following head injuries or concussion in sportsmen involved in contact sports. More...


The enzyme-linked immunosorbent assay (ELISA) measured the levels of the astrocytic protein S100B which is normally only found in the brain, but leakage into the blood indicates blood-brain barrier disruption (BBBD) which may cause an immune response associated with production of autoantibodies.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and the University of Rochester (NY, USA) enrolled 67 volunteers from three American college football teams and collected blood samples before and after matches. The serum levels of S100B and autoantibodies against S100B were measured and correlated by direct and reverse immunoassays. Computerized cognitive testing, diffusion tensor imaging, and an estimation of head hits were also carried out.


The S100B measurements were performed using an ELISA kit (Diasorin; Saluggia, Italy) and reading carried out on a multiplate fluorescent reader. Fluorescent signals were converted into ng/mL as per standard curve concentrations. Serum S100B autoantibody measurements were optimized using a monoclonal antibody (Meridian Life Science Inc.; Cincinnati, OH, USA) in an ELISA system and read on a plate reader at 490 nm.


The investigators found elevations of serum S100B indicating blood-brain barrier disruption occur in football players who experience subconcussive head hits (SHH) below the threshold for a diagnosis of concussion. They also showed that players who during a season experience the most significant repeated elevations of S100B are also those with the highest titer of serum S100B autoantibodies. Out of the 27 players who had preseason S100b blood levels measured, four showed signs of an autoimmune response to the protein. Brain tissue damage was confirmed in the players through a series of brain scans.


Damir Janigro, PhD, the senior author of the study said, "Think of the blood-brain barrier disruption as opening a door to the brain that should not be open. Proteins like S100B, which normally stay inside the brain, get out where they are not supposed to be and get attacked. In addition, the door is open for things that do not belong in the brain to get in." The blood test is a great deal less expensive at around USD 40 than other means of evaluating the extent of head trauma, such as computed axial tomography (CAT) scans. The study was published on March 6, 2013, in the journal Public Library of Science ONE (PLOS ONE).

Related Links:

Cleveland Clinic
University of Rochester
Diasorin



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.